GenSight Biologics S.A.
GSGTF
$0.19
-$0.05-20.79%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 128.10K | 128.60K | -124.30K | -115.20K | 220.10K |
| Total Other Revenue | 223.50K | 224.50K | 151.50K | 140.50K | 258.00K |
| Total Revenue | 351.60K | 353.10K | 27.20K | 25.30K | 478.10K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 351.60K | 353.10K | 27.20K | 25.30K | 478.10K |
| SG&A Expenses | 1.58M | 1.59M | 1.45M | 1.34M | 1.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.83M | 2.85M | 3.88M | 3.60M | 4.96M |
| Operating Income | -2.48M | -2.49M | -3.85M | -3.57M | -4.48M |
| Income Before Tax | -2.95M | -2.96M | -3.96M | -3.67M | -4.34M |
| Income Tax Expenses | 2.30K | 2.30K | -5.10K | -4.70K | 8.50K |
| Earnings from Continuing Operations | -2.95M | -2.96M | -3.95M | -3.67M | -4.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.95M | -2.96M | -3.95M | -3.67M | -4.35M |
| EBIT | -2.48M | -2.49M | -3.85M | -3.57M | -4.48M |
| EBITDA | -2.44M | -2.45M | -3.81M | -3.53M | -4.22M |
| EPS Basic | -0.02 | -0.02 | -0.03 | -0.03 | -0.04 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.02 | -0.02 | -0.03 | -0.03 | -0.04 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 168.40M | 168.40M | 128.27M | 128.27M | 108.76M |
| Average Diluted Shares Outstanding | 168.40M | 168.40M | 128.27M | 128.27M | 108.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |